B. Moy ET AL: "HEPATOBILIARY ABNORMALITIES IN PATIENTS WITH METASTATIC CANCER TREATED WITH LAPATINIB", Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 27, No 15S (May 20 Supplement), 1 January 2009 (2009-01-01), page 1043, XP055080845, Retrieved from the Internet: URL:http://meeting.ascopubs.org/cgi/conten t/abstract/27/15S/1043 [retrieved on 2013-09-24] (B1)

GLAXOSMITHKLINE: "HLA-DQA1*0201 is a major determinant of lapatinib-induced hepatotoxicity risk in women with advanced breast cancer", 20100324, 24 March 2010 (2010-03-24), pages 1-14, XP007922274, (B1)

J O'donohue ET AL: "Co-amoxiclav jaundice: clinical and histological features and HLA class II association", Gut, 1 January 2000 (2000-01-01), pages 717-720, XP055080846, Retrieved from the Internet: URL:http://gut.bmj.com/content/47/5/717.fu ll.pdf#page=1&view=FitH [retrieved on 2013-09-24] (B1)

ZUBILLAGA ET AL.: 'HLA-DQA1 and HLA-DQB1 Genetic Markers and Clinical Presentation in Celiac Disease' JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION vol. 34, May 2002, pages 548 - 554 (B1)

US-A1- 2007 281 041 (B1)

US-A1- 2009 192 101 (B1)

WEST: 'Malignancy and mortality in people with coeliac disease: population based cohort study' BMJ vol. 329, no. 7468, 21 July 2004, (B1)

ROSES: 'Pharmacogenetics in drug discovery and development: a translational perspective' NATIONAL DRUG DISCOVERY vol. 7, October 2008, pages 807 - 817 (B1)